REFERENCES
1. Wolfe AD. Pediatric Vascular Anomalies: Opportunities in Primary
Care. In: Kamat DM, Frei-Jones M, eds. Benign Hematologic
Disorders in Children: A Clinical Guide. Cham: Springer International
Publishing; 2021:453-486.
2. Anomalies ISftSoV. ISSVA Classification of Vascular Anomalies. 2018;
https://www.issva.org/classification. Accessed March 2, 2021.
3. Canaud G, Hammill AM, Adams D, Vikkula M, Keppler-Noreuil KM. A
review of mechanisms of disease across PIK3CA-related disorders with
vascular manifestations. Orphanet Journal of Rare Diseases.2021;16(1):306.
4. Trenor CC, Adams DM, eds. Vascular Anomalies: A Guide for the
Hematologist/Oncologist. 1 ed. Switzerland: Springer International
Publishing; 2020.
5. Kerr AM, Haas SM. Parental uncertainty in illness: managing
uncertainty surrounding an ”orphan” illness. Journal of pediatric
nursing. 2014;29(5):393-400.
6. Kerr AM, Harrington NG, Scott AM. Communication and the Appraisal of
Uncertainty: Exploring Parents’ Communication with Credible Authorities
in the Context of Chronic Childhood Illness. Health
communication. 2017;34(2):201-211.
7. Kerr AM, Harrington NG, Scott AM. Uncertainty Management and Decision
Making: Parents’ Experiences During their First Visit to a
Multidisciplinary Clinic for their Child’s Vascular Anomaly.Journal of pediatric nursing. 2020;52:18-24.
8. Kerr AM, Thompson CM, Rubinsky V. Memorable Messages Parents of
Children with Vascular Birthmarks Receive from Others: Implications for
Stigma and Identity. Health communication. 2020;35(6):685-695.
9. Hammill AM, M. W, A. G, et al. Sirolimus for the treatment of
complicated vascular anomalies in children. Pediatric Blood and
Cancer. 2011;57(6):1018-1024.
10. Adams DM, Trenor CC, 3rd, Hammill AM, et al. Efficacy and Safety of
Sirolimus in the Treatment of Complicated Vascular Anomalies.Pediatrics. 2016;137(2):e20153257.
11. Ji Y, Chen S, Yang K, et al. A prospective multicenter study of
sirolimus for complicated vascular anomalies. J Vasc Surg. 2021.
12. Harbers VEM, Rongen G, van der Vleuten CJM, et al. Patients with
Congenital Low-Flow Vascular Malformation Treated with Low Dose
Sirolimus. Adv Ther. 2021.
13. Maruani A, Tavernier E, Boccara O, et al. Sirolimus (Rapamycin) for
Slow-Flow Malformations in Children: The Observational-Phase Randomized
Clinical PERFORMUS Trial. JAMA Dermatol. 2021.
14. Shimano KA, Eng W, Adams DM. How we approach the use of sirolimus
and new agents: Medical therapy to treat vascular anomalies.Pediatr Blood Cancer. 2022:e29603.
15. Ricci KW, Iacobas I. How we approach the diagnosis and management of
complex lymphatic anomalies. Pediatr Blood Cancer. 2021:e28985.
16. Queisser A, Seront E, Boon LM, Vikkula M. Genetic Basis and
Therapies for Vascular Anomalies. Circ Res. 2021;129(1):155-173.
17. O’Shea AE, Valdera FA, Ensley D, et al. Immunologic and dose
dependent effects of rapamycin and its evolving role in chemoprevention.Clin Immunol. 2022;245:109095.
18. Rossler J, Eulalia B, Victoria D, et al. Severe adverse events
during sirolimus ”off-label” therapy for vascular anomalies.Pediatric blood & cancer. 2021;68(8):e28936.
19. Adams DM, C. TC, M. HA, et al. Efficacy and safety of sirolimus in
the treatment of complicated vascular anomalies. Pediatrics.2016;137(2).
20. Maruani A, E. T, O. B, et al. Sirolimus (Rapamycin) for Slow-Flow
Malformations in Children: The Observational-Phase Randomized Clinical
PERFORMUS Trial. JAMA Dermatology. 2021;157(11):1289-1298.
21. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA Statement for
Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate
Health Care Interventions: Explanation and Elaboration. PLOS
Medicine. 2009;6(7):e1000100.
22. Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T.
De-duplication of database search results for systematic reviews in
EndNote. J Med Libr Assoc. 2016;104(3):240-243.
23. Munn Z, Barker TH, Moola S, et al. Methodological quality of case
series studies: an introduction to the JBI critical appraisal tool. JBI
Evidence Synthesis. 2020;18(10):2127-2133.
24. Ji Y, S. C, J. Z, et al. Sirolimus plus prednisolone vs sirolimus
monotherapy for kaposiform hemangioendothelioma: a randomized clinical
trial. Blood. 2022;139(11):1619-1630.
25. Russell TB, K. RE, S. DC, B. GL, W. MT. Pneumocystis jirovecii
pneumonia during sirolimus therapy for kaposiform hemangioendothelioma.Pediatrics. 2018;141:S421-S424.
26. Mäkinen T, Boon LM, Vikkula M, Alitalo K. Lymphatic Malformations:
Genetics, Mechanisms and Therapeutic Strategies. Circ Res.2021;129(1):136-154.
27. Malpica L, Moll S. Practical approach to monitoring and prevention
of infectious complications associated with systemic corticosteroids,
antimetabolites, cyclosporine, and cyclophosphamide in nonmalignant
hematologic diseases. Hematology Am Soc Hematol Educ Program.2020;2020(1):319-327.
28. Malpica L, van Duin D, Moll S. Preventing infectious complications
when treating non-malignant immune-mediated hematologic disorders.Am J Hematol. 2019;94(12):1396-1412.
29. Wang Z, W. Y, H. S, et al. Sirolimus therapy for kaposiform
hemangioendothelioma with long-term follow-up. Journal of
Dermatology. 2019;46(11):956-961.
30. Wang Y, L. K, B. S, J. C, W. S. Sirolimus for Kaposiform
Hemangioendothelioma With Kasabach-Merritt Phenomenon in Two Infants.The Journal of craniofacial surgery. 2020;31(4):1074-1077.
31. Ying H, C. Q, X. Y, X. L. A case report of 2 sirolimus-related
deaths among infants with kaposiform hemangioendotheliomas.Pediatrics. 2018;141:S425-S429.
32. Sandbank S, V. M-P, A. F, A. B, S. G. Oral and topical sirolimus for
vascular anomalies: A multicentre study and review. Acta
Dermato-Venereologica. 2019;99(11):990-996.